

Isotopes for Life

Advanced Nuclear Medicine Initiative



Owen Lowe
Office of Isotopes for Medicine and Science
Office of Nuclear Energy,
Science and Technology

October 1, 2002



Advanced Nuclear Medicine Initiative


- Sponsor nuclear medical science research using a peer-review selection process
 - 9 three-year research grants awarded
- Sponsor the training of individuals in nuclear medical science



- 5 three-year education grants awarded
- Continue research and education programs to completion; however, no additional funds for new grants is in the FY 2003 budget




ADVANCED NUCLEAR MEDICINE INITIATIVE Research & Development Projects





ADVANCED NUCLEAR MEDICINE INITIATIVE Education Programs





Advanced Nuclear Medicine Initiative Research Awards

The Curators of the University of Missouri

- Development of Production Methods for Carrier-Free Lanthanides for Radiotherapy
- In Vivo Selection of Novel Prostate Tumor-Avid Fab

Garden State Cancer Center

- Bi-Specific Antibody for Cancer Therapy
- Briefed at Stakeholder Meeting in Toronto (June 2001)

Oak Ridge National Laboratory

- Improved Generators for Clinical Use of Bi-213
- Briefed at the Financial and Business Meeting (February 28, 2002)

The Regents of the University of Michigan

- Development of Radioactive Nanocomposites to Treat Tumors Microvasculature
- Paper accepted for publication in Ogge Chemical/Chemistry Today
- Two papers submitted to SNM (June 2002)

University of California-Davis

- A Modular Tumor Targeting System to Deliver Pretargeted Alpha and Beta Radioisotope Therapy
- Briefed DOE in Toronto (June 2001)



Advanced Nuclear Medicine Initiative Research Awards (cont.)

The University of Chicago

- The Application of Microdosimetry to Analyze and Predict Cell Survival Following Alpha-Particle Irradiation
- Briefed during visit (May 2001)

University of Washington

- Evaluation of Reagents for Rapid and Stable Labeling of Biomolecules with Astatine-211
- Briefed at Stakeholders Meeting in Toronto (June 2001)

Westinghouse Electric Company LLC

- Separation of Medically Useful Alpha-Emitting Isotopes Using Nonchemical Recoil Ion Methods
- Copies of Annual Report distributed to program personnel

0

Advanced Nuclear Medicine Initiative Education Awards

Board of Regents of the University of Wisconsin System

 The University of Wisconsin Training Program for MS-Level PET Medical Physicists

Purdue University

Purdue University Nuclear Pharmacy Educational Program

University of New Mexico Health Sciences

Nuclear Pharmacy Graduate Education

Washington State University

 Establishment of a Nuclear Pharmacy Graduate Certificate Program at WSU Tri-Cities


Washington University

Graduate Research in Nuclear Medicine at Washington University



Advanced Nuclear Medicine Initiative Research Grants

ANMI FY 2000 Award Funding Profile



Funds Available: Approximately \$2.0 million



ANMI Results

Published 5 articles in professional journals

Examples:

Proclinical Development of Anti-MUC-1 scFv for Targeted Radioisotope Therapy; Winthrop, M.D., S.J. DeNardo, G.R. Mirick, L.A. Kroger, K.R. Lamborn, C. Venclovas, M.E. Colvin, and G.L. DeNardo; Submitted to Clinical Cancer Research

Dendrimer Nanocomposites in Medicine; L. Balogh, A. Bielinska, J.D. Eichman, R. Valluzzi, I. Lee, J.R. Baker, T.E. Lawrence, and M.K. Khan; Chimica Oggi/Today, Vol. 20, No. 5 (May 2002)



ANMI Results

Presented 12 papers at scientific meetings

Examples:

Separation of the Alpha-emitting Radioisotopes Actinium-225 and Bismuth-213 from Thorium-229 Using Alpha Recoil Methods; F.H. Ruddy, A.R. Dulloo, J.G. Seidel, and B. Petrovic; Westinghouse Electric Company, LLC; presented at the Topical Meeting on Industrial Radiation and Radioisotope Measurement Applications, Bologna, Italy, June 11, 2002

Biodistributions of Stereptavidini/CC49 scFv₄-Pretargeted ¹⁴⁹Pm-, ¹⁶⁶Ho- and ¹⁷⁷Lu-Dota-Biotin in Tumor Bearing Mice; J. Zhang, N.K. Owen, C.S. Cutler, M.F. Embree, F. Jia, D. Mazuru, A.D. Lewis, J. Schultz, L.J. Theodore, A.R. Ketring, S.S. Jurisson, D.B. Axworthy, and M.R. Lewis, University of Missouri, Columbia, MO, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, and NeoRx Corporation, Seattle, WA; presented at the 49th Annual Society of Nuclear Medicine Meeting in Los Angeles, CA, June 2002